Journal of the European Academy of Dermatology and Venereology | 2021
Rare cutaneous adverse effects of COVID‐19 vaccines: a case series and review of the literature
Abstract
Among the vaccines against coronavirus disease 2019 (COVID-19), BNT162b2 from BioNtech-Pfizer and mRNA-1273 from Moderna are mRNA vaccines targeting the Spike protein of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The ChAdOx1 nCoV-19 (AZD1222) from Oxford-AstraZeneca is based on adenovirus expressing the full-length Spike protein. Clinical trials reported different cutaneous adverse events, mainly local injection site reactions, either immediate or delayed on/after 8 days.